Boehringer announces positive cardiovascular outcomes for linagliptin. Credit: © Boehringer Ingelheim.

Boehringer Ingelheim and Eli Lilly have reported positive results from the CAROLINA cardiovascular outcomes trial of Tradjenta (linagliptin) in type 2 diabetes patients.

The trial met its primary endpoint of non-inferiority for Tradjenta over glimepiride in duration to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3P-MACE).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Tradjenta is a dipeptidyl peptidase-4 (DPP-4) inhibitor intended for use alongside a diet and exercise to lower blood sugar in adults with type 2 diabetes.

Type 2 diabetes patients are known to be at higher risk of cardiovascular disease, which remains the main cause of death for this population.

The multi-national, randomised, double-blind, active-controlled CAROLINA trial evaluated Tradjenta’s long-term impact, efficacy, and safety on cardiovascular morbidity and mortality.

“Tradjenta is an important option for physicians considering a DPP-4 inhibitor for their patients with type 2 diabetes.”

It monitored 6,033 patients over a median time frame of six years at more than 600 sites in 43 countries and compared a once-daily 5mg dose of Tradjenta with sulfonylurea glimepiride.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The overall safety profile of Tradjenta was observed to be consistent with available data and no new signals were reported.

Lilly Diabetes Product Development vice-president Jeff Emmick said: “These data provide further confidence in the well-established safety and tolerability profile of Tradjenta for the treatment of adults with type 2 diabetes.

“Tradjenta is an important option for physicians considering a DPP-4 inhibitor for their patients with type 2 diabetes. Boehringer Ingelheim and Lilly look forward to sharing the full results later this year.”

Tradjenta was previously evaluated in another cardiovascular outcomes trial called CARMELINA.

This trial studied 6,979 type 2 diabetes patients for a median duration of 2.2 years at more than 600 sites in 27 countries.